Organon & Co. (OGN)

Organon & Co.'s stock price has experienced significant volatility and a downward trend over the past six months. Key events impacting the stock include the conclusion of an audit in February 2026, the Q4 and full-year 2025 earnings report, a dividend cut, and hitting a new 52-week low in late March 2026.

Demand seasonality for Organon's products can be observed in certain areas. There was a pickup in demand for respiratory products in countries outside of Japan within the Asia Pacific region in the first quarter of 2023. Strong demand for fertility products has been noted, driven by factors such as the reopening of China and sustained demand in the United States. The company also experienced a solid uptick in its Women's Health segment revenues in Q1 2024, primarily due to the strength of Nexplanon.

Organon & Co. is a global healthcare company specializing in developing and delivering health solutions, operating within the Pharmaceuticals sector. Its business is divided into women's health, biosimilars, and established brands. The women's health portfolio includes contraception and fertility brands. The biosimilars segment focuses on immunology and oncology treatments. The established brands franchise comprises over 70 products across various therapeutic areas.

Organon & Co. has a significant global presence, with products available in over 140 countries and territories. The company has a direct footprint in 62 countries and maintains collaborations in more than 80 others. The majority of its revenue is generated from outside the United States, with key revenue-generating regions including Europe and Canada, the United States, and the Asia Pacific and Japan regions.

Organon's brand reputation has been influenced by challenges and efforts to maintain transparency. The resignation of its former CEO impacted its reputation, prompting a focus on strengthening internal controls. However, an independent audit review found no improper conduct related to biosimilar purchases, which helped alleviate uncertainty. Organon's mission to improve women's health globally and its commitment to ESG priorities also contribute to its brand image.

Organon & Co.'s ownership structure is a mix of institutional, retail, and individual investors. As of December 2025, institutional firms held 74.3% of the company's shares. Insider buying activity was noted in 2025. Major institutional owners include Vanguard Group Inc, BlackRock, Inc., and State Street Corp.